摘要
目的：探讨坦度螺酮治疗原发性高血压伴焦虑症状患者的临床疗效和安全性。方法将60例原发性高血压伴焦虑症状患者按入组顺序分为两组，均口服缬沙坦常规降压治疗，研究组在此基础上口服坦度螺酮治疗，观察8周。治疗前后监测血压变化，采用汉密顿焦虑量表评定焦虑状况，中国心血管病人生活质量评定问卷评定生活质量，副反应量表评定不良反应。结果治疗8周末研究组汉密顿焦虑量表总分较治疗前显著下降，中国心血管病人生活质量评定问卷各维度评分较治疗前显著升高（P＜0．01），对照组治疗前后评分均无显著变化（P＞0．05）；研究组降压总有效率为73．3％，对照组为46．7％，研究组显著高于对照组（χ2＝4．44，P＜0．05）。研究组出现倦怠、口干、便秘、胃肠道不适发生率高于对照组，但两组副反应量表评分比较差异无显著性（P＞0．05）。结论对原发性高血压伴焦虑症状患者在常规应用降压药物的基础上联合坦度螺酮治疗，能显著改善患者的焦虑症状、提高降压疗效和生活质量，安全性高，优于单用降压药物治疗。
Objective To explore the efficacy and safety of tandospirone in essential hypertension patient with anxious symptoms .Methods Sixty essential hypertension patient with anxious symptoms were as‐signed to two groups according to enrollment order ,both gropups took orally valsartan ,on this basis re‐search group was plus oral tandospirone for 8 weeks .Before and after treatment blood pressure （BP） chan‐ges were monitored ,anxiety conditions assessed with the Hamilton Anxiety Scale （HAMA） ,qualities of life with China Cardiovascular Quality of Life Questionnaire （CCQQ ） ,and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results At the end of the 8th week the HAMA total score lowered more significantly and each dimension score of the CCQQ heightened （P〈 0 .01） compared with pretreatment in research group ,those had no significant changes in control group （P〉0 .05）;total effec‐tive rate of depressurization was respectively 73 .3% in research and 46 .7% in control group ,the former was significantly higher than the latter （χ2 = 4 .44 ,P〈 0 .05） .The incidences of tiredness ,dry mouth , constipation and gastrointestinal indisposition were higher in research than in control group ,there was no significant group difference in the TESS scores （P〉0 .05） .Conclusion Routine antihypertensive drug plus tandospirone could notably improve anxious symptoms ,depressurization efficacy and quality of life and has higher safety compared with single antihypertensive drug in essential hypertension patient with anxious symptoms .
出处
《临床心身疾病杂志》
CAS
2015年第3期57-59,共3页
Journal of Clinical Psychosomatic Diseases
